As a result, this clinical course may provide some important insights for the long-term management of such patients. Details of previous NSCLC cases with an EGFR mutation and choroidal metastasis, treated with an EGFR-TKI as a first-line treatment, are provided in Table 1. This evidence concerns the gene EGFR and non-small cell lung carcinoma.